Zevra Therapeutics (NASDAQ:ZVRA) CEO Sells $225,000.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil Mcfarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $11.25, for a total value of $225,000.00. Following the completion of the transaction, the chief executive officer directly owned 417,225 shares in the company, valued at approximately $4,693,781.25. This represents a 4.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zevra Therapeutics Trading Up 0.4%

ZVRA opened at $10.27 on Friday. The business has a 50 day moving average of $11.50 and a 200-day moving average of $11.42. The stock has a market capitalization of $609.83 million, a price-to-earnings ratio of 6.47 and a beta of 0.98. Zevra Therapeutics, Inc. has a 1-year low of $8.01 and a 1-year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. Equities analysts predict that Zevra Therapeutics, Inc. will post 0.72 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on ZVRA shares. Guggenheim decreased their price target on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 27th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 19th. Finally, HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a research report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $27.14.

Institutional Trading of Zevra Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ZVRA. AIGH Capital Management LLC bought a new position in Zevra Therapeutics in the first quarter worth $11,184,000. Bank of New York Mellon Corp acquired a new stake in Zevra Therapeutics during the second quarter worth $2,846,000. Dimensional Fund Advisors LP boosted its stake in Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after buying an additional 400,336 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in Zevra Therapeutics by 116.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after buying an additional 206,543 shares in the last quarter. Finally, Globeflex Capital L P bought a new stake in Zevra Therapeutics in the 2nd quarter valued at $2,752,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.